<unk>  received US FDA and EU European Medicines Agency approval in September 2012, and March 2013, respectively for the treatment of adults with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.
Bosutinib
Ibrutinib
Imatinib
Acalabrutinib
Ponatinib
Afatinib
Ceritinib
Ruxolitinib